Roberto Gorni works in the Technical Regulations Area of Cosmetica Italia, The personal care Association. He is expert in cosmetic’s regulatory and he provides advice and support in the technical-productive and law field applied to the manufacturing and marketing of cosmetic products. He is a member of several national and international working groups in the cosmetic technical field, and he is frequently a speaker at major conferences and seminars on cosmetic legislation.
Graziano Castaldi devoted his career to design and develop innovative processes for manufacturing Active Pharmaceutical Ingredients including also Cosmetic Active Ingredient. He covered the responsibility for R&D in important pharmaceutical European companies providing support in the technical-productive and marketing. Since 2008 he is founder and main shareholder of a R&D company, Chemelectiva, providing the services to the main generic pharmaceutical as well as cosmetic companies. He is author of many scientific publications and patents and lecturer at several national and international schools, conferences and seminars.
Luisa Fiandra is Researcher and Aggregate Professor in Cytology and Comparative Anatomy at the Department of Earth and Environmental Sciences, University of Milano Bicocca (UNIMIB), Italy, and she is member of the Research Center POLARIS (Particular Matter and Health Risk) and of the Nanotoxicology Laboratory of UNIMIB.
2017 – Lab Manager of NanoBioLab, Department of Biotechnology and Biosciences (BtBs), UNIMIB.
2010 – Senior researcher and scientific coordinator of the project “Development of novel nanostructured materials for the diagnosis of breast cancer, inflammatory bowel disease (IBD) and modulation of antiretroviral therapy (HAART) in HIV” (financed by Regione Lombardia), Nanomedicine Unit of the Department of Biomedical and Clinical Sciences L. “Sacco”, University of Milano (UNIMI)
2003 – PhD in Invertebrate Biology; 1998, M.Sc. in Life Sciences, UNIMI.
From 2010 to 2017, LF coordinated pre-clinical studies mainly devoted to the use of nanotechnology for cancer therapy and diagnosis, and for biological barriers overcoming. From 2018 LF is involved in the safety evaluation of different types of nanoproducts by in vitro and in vivo (Zebrafish) assays. Within the current project PROTECT (EU Program H2020), the main area of interest is the safety of metal oxides nanoparticles on 3D in vitro skin models according to standardized protocols (OECD, ISO).
LF is author of 31 publications in peer-reviewed journals.
After a PhD in Cosmetic Science and Technology, in 1999 Francesca Bernacchi was enrolled in Cosmetica Italia, the personal care association. In 2008 she joined the Technical – Regulatory Area, where she is still working, giving technical and scientifical support and to member companies. She is an expert in cosmetic, REACH an CLP regulations, participating in several expert teams and working groups at both national and international level. She is frequently invited as a speaker in meetings and seminars .
Francesca Granucci is Full Professor at the University of Milano-Bicocca since 2016 and director of the laboratory of Innate Immunity at INGM, Milan since 2019. She received her PhD in Pharmacology and Toxicology from the University of Milan in 1996. She then performed the Post doc at the Dana Farber Cancer Institute – Boston. From 1998 to 2001 she worked as Research Associate at the CNR in Milan, from 2001 to 2006 she worked as Research Associate at the University of Milano-Bicocca and from 2006 to 2016 she was Associate Professor at the University of Milano-Bicocca. She has pioneered systems biology approaches to study complex dynamic processes, such as host-pathogen interactions and the process of dendritic cell maturation. More recently she focused her research activity on signalling events downstream of Pattern Recognition Receptors within cells of the mammalian innate immune system and she identified some of the key functions played by the NFATc family of transcription factors activated in phagocytes in response to PRR agonists
Luca Munaron is Full Professor of Physiology in the Department of Life Sciences and Systems Biology (University of Torino, Italy).
He is member of the Italian Society for Cardiovascular Research (SIRC), the Italian Physiological Society (SIF), the Scientific Board for the Doctoral School in Life and Health Sciences (Univ of Torino) and the Interuniversity Research Centre on Epistemology and History of Life Sciences- Res Viva (Univ of Rome).
In 1997 he founded the Laboratory of Cellular and Molecular Angiogenesis, and authored more than 100 papers on international Journals. His main research interest is focused on the cellular mechanisms involved in the physiology and patology of the vascular system. He wrote two books and several book reviews in italian, mainly on Evolutionary Physiology and History and Philosophy of Biology.
He attended tens of national and international Congresses and Meetings as invited speaker and chairman and served as reviewer for high impact international journals and research grants.
Since 2011 he is scientific supervisor for University-Industry agreements.
The major research interest of Stefania Recalcati, Associate Professor – University of Milan, is the molecular regulation of iron metabolism. She is currently very active in studying the different expression of iron proteins in various populations of macrophages, thus contributing to dissect peculiar and specific functional roles of polarized macrophages in various pathological conditions. Her studies provided relevant information to understand the molecular basis of iron retention in macrophages during inflammation, an event involved in the pathogenesis of the anemia of chronic diseases. She also started to study iron metabolism in cancer, producing, for example, strong evidences on its key role in cholangiocarcinoma development and progression.
Less recently she also took part in studies regarding the modifications of iron metabolism under conditions of increased erythropoiesis and pathological conditions, such as oxidative stress and inflammation. In the past she studied and described the abnormal expression of iron-related proteins in hereditary hemochromatosis.
Dr. Selmi received his MD in 1998 and his PhD in Internal Medicine in 2002, both from the University of Milan. He was appointed Assistant Professor by the same University for Internal Medicine in 2006 and for Rheumatology since 2011. In 2004 he was awarded the Young Researcher prize by the Italian Society of Internal Medicine and in 2005 the Young Investigator Award by the Aesku-Kipp Foundation. Dr. Selmi was a post-doctoral researcher between august 2001 and december 2004 at the Division of Rheumatology, Allergy, and Clinical Immunology of the University of California, Davis School of Medicine. Since July 2005, he was appointed Assistant Adjunct Professor of Medicine by the same Division at UC Davis.
Carlo Selmi currently leads the Rheumatology and Clinical Immunology Unit at Humanitas research hospital. At Humanitas he leads a young group of physician scientists with wide research and clinical expertise, including periods working at foreign institutions. The team holds dedicated clinics for rheumatoid arthritis, spondiloarthritis, connective tissue disease with dedicated clinics for systemic sclerosis and systemic lupus erythematosus, and is active in articular ultrasound, videocapillaroscopy, arthrocenthesis and intra-articular injections.
He has coauthored over 300 peer-reviewed publications with a Scopus H index of 55 and a total impact factor exceeding 2000. His research track is dedicated to organ-specific and systemic autoimmune and chronic inflammatory diseases, including the clinical epidemiology and pathogenetic mechanisms of autoimmune liver disease, connective tissue disease (particularly systemic sclerosis), and psoriatic arthritis. His work has been funded by the National Institutes of Health, American Liver Foundation, American Scleroderma Foundation, Italian Ministry of Health, Italian Ministry of Foreign Affairs, and the Lilly Research Foundation.
Francesco Di Pierro
Francesco Di Pierro is the Scientific Director of Velleja Research a company whose aim is to provide the biopharmaceutical development of products, whether dietary supplements, medical devices, cosmetics or medicines
Thanks to his passion for pharmacological, phytotherapeutic and nutritional sciences, Di Pierro’s interest follows the need for rational ideation and scientific development of new products/preparations for the pharmaceutical, nutraceutical and cosmetic sectors, as well as of medical devices with particular regard to the branch of dietary supplements and phytotherapeutic remedies.
She received her master degree in Sanitary Biology at the University of Turin in 2007. In 2013 she obtained the title of PhD in Experimental Medicine and Therapy (Cardiovascular Physiology) at the University of Turin, Italy.
After the PhD she started her post-doctoral activity in the Cellular and Molecular Angiogenesis Laboratory at the Department of Life Sciences and Systems Biology, Turin, Italy. Her research focuses on the characterization of the paracrine communication between cells that populate dermal/epidermal interface and sub-cutaneous vasculature. In collaboration with pharmaceutical companies she pays her attention on the characterization of the role of natural alternative strategies during skin alteration (i.e. Androgenetic Alopecia) using in vitro co-culture and tri-culture approaches.
Alessio Tacchi, Master degree in Chemistry and Pharmaceutical Technologies in UPO in 2003, is the Head of Process Technology in Procos, an important API manufacturer in the Novara Area. Along his career he has gained excellent experience in the scale-up of industrial chemical processes, besides in their optimization and technology transfer on different productive lines, with more than 25 chemical processes successfully scaled-up and industrialized, for more than 100 different synthetic steps. His experience gave him an excellent knowledge in the plants for the batch production of APIs and pharmaceutical intermediates as well as an excellent experience in plant management, setting-up, modification and improvement.
Andrea Cavagnino, Study Director at OxiProteomics, PhD in Science of Bioactive Molecules and interested in the molecular mechanisms of aging and aging-associated diseases.
After several years of international research in Italy, UK and France, he joined OxiProteomics in 2015, an innovative technology-driven biotech company in Paris, providing science-based solutions to promote healthy living and healthy aging of human population.
Plastic and maxillofacial surgeon with broad experience and highly innovative approach.
Regenerative medicine has become a major focus after patenting Lipogems technology in 2010 with strong collaborative ties with major world institutions. The focus remains in translational clinical research with thousands of patients treated and followed and teaching courses on Lipogems use worldwide.
- 1983-1989 School of Medicine and Surgery – University of Milan, Italy Medical degree (October 1989)
• 1989-1994 Post-graduate school of Plastic and Reconstructive Surgery – University of Parma – Specialization in Plastic Reconstructive and Aesthetic Surgery (July 1994)
• 1994-1996 Department of Plastic Surgery – Lodi Hospital, Legnano Hospital, Niguarda Hospital Internship and collaboration in research projects and teaching courses
•1996-2004 Post-graduate school of Maxillo-facial surgery – University of Parma Contract Professor (course: surgical anatomy of the face )
• Sept 1996-May 2010 Chief of Plastic Surgery sevice, Department of Maxillo-facial Surgery, San Paolo Hospital Reconstructive surgery of acquired and congenital anomalies of the face and body
• 1999-2003 Post-graduate school of Maxillo-facial surgery Specialization in Maxillo-facial surgery (July 2003)
• 2005-2010 School of Dentistry – University of Florence
Contract Professor (course: plastic and reconstructive surgery of the face)
• Feb 2010-May 2010 Adjunct professor DRI institute – University of Miami
Research on adipose derived mesenchimal stem cell (DRI federation)
• May 2010- Consultant Plastic and Maxillo-facial surgeon in different public and private Institutions and universities
- Head of Istituto image Srl
Marisa Gariglio MD, PhD, is Professor of Medical Microbiology at the Medical School of Novara, University of Piemonte Orientale, Novara-Italy. She received her degree in Biology in 1984 and her Medical degree in 1990 from the University of Turin-Italy, where she also completed her PhD program in Immunology and Virology. After post-doctoral training at the Department of Molecular Biology “Hoffmann La Roche” (Basel-Switzerland) studying transcriptional regulation of interferon-inducible genes, she joined the Novara Medical School in 1996 as Assistant Professor. Since 2001, she is full professor and P.I. of the laboratory of Molecular Virology. Her laboratory has interests in the pathogenesis, molecular genetics and biochemistry of human papillomaviruses (HPV). Emphasis has been placed on understanding betaHPV-epithelial keratinocyte interactions in naturally occurring patient lesions, such as skin cancer developing in immunosuppressed patients (including organ transplant recipients) and patients suffering from primary immunodeficiency (including Epidermodysplasia verruciformis), and on developing experimental model skin systems (organotypic raft cultures and transgenic mice) that closely reflect these events. Her background is also including the interferon system, particularly the role of the DNA sensor IFI16 in intrinsic antiviral immunity against cytomegalovirus and papillomavirus. At present her h-index is 35.
Andrea MALTAGLIATI is the Market Manager for Personal Care in Roelmi HPC. He is in charge of planning medium-long term strategies by looking at worldwide market trends. Thanks to the acquired know-how in the biofermentation processes, Andrea is also Product Manager for Biotechnology product lines such as PrincipHyal full spectrum hyaluronans. After an initial experience as technical director in an Italian distribution company for cosmetic, he gradually gained experience developing business in other European countries (and worldwide) as marketing manager, export manager and sales manager. Andrea MALTAGLIATI joined Principium Europe in 2012, where he helped build the strong company reputation as supplier of active ingredients, thanks to his technical background and international expertise. Before joining to Roelmi HPC he had an experience as Product Manager for 3 years in a multinational company. Graduated in Chemistry at Milan University, Andrea naturally owns innate effective communication skills and speaks fluent English.
Mercedes Procopio received her degree in Chemistry and her specialization in Cosmetic Science and Technologies at the University of Milan. Since 1999 she has been involved in the Regulatory Affairs sector at companies that produce make-up for third parties. Since 2015 she in Regulatory Affairs Manager at Art Cosmetics. She belongs to the Technical Committee and she is also President of Cosmetica Italia, the Italian personal care association.
Yves Geysels is Visiting Professor of Clinical Trials at the Faculty of Medicine, Department of Biomedical Sciences and has authored more than 50 publications. Currently he is also Director of Clinical Operations at Bone Therapeutics, a bone cell therapy company, specializing in addressing unmet medical needs in the field of orthopaedics and bone diseases. Yves has a vast experience of more than 20 years in managing clinical trials from an operational point of view, within pharmaceutical companies and Contract Research Organizations (CRO), prior joining the Biotech Industry in 2018. He is founder and honorary president of the Belgian Association of Clinical Research Professionals (ACRP.be) and a honorary fellow at the University of Brussels (VUB).
After a PhD in Molecular Biology, she worked in private companies in the field of drug development, in different roles covering all aspects of quality assurance and regulatory requirements. As director of operations in accredited labs, she has lead the development and validation of analytical methods used in ISO17025/CLIA/GLP/GCLP/GMP regulatory contexts. As head of production in a CMO specialized in the production of viral vectors, she has supervised the GMP compliance of activities in a sterile/BL3 environment. As head of a clinical unit, she has managed the conduct of phase one clinical trials. Currently director of operations in a company in charge of the supply chain of clinical trials, she supervises the packaging and labelling of IMP, their storage and distribution, as well as the biobanking of human samples.
Laure Delbecque holds a PhD in psychological sciences, as well as a Master’s degree in neuropsychology and cognitive psychology awarded by the Université Libre de Bruxelles, Belgium. She is currently Research Scientist at Eli Lilly in the Patient-Focused Outcomes center of expertise. Before joining Lilly, Laure held positions as expert in patient-reorted outcomes (PRO), (e)PRO researcher, Data Management Specialist, and Publication Manager in major consultancy companies. She was also a teaching assistant for statistics applied to human sciences at the Université Libre de Bruxelles and is currently visiting professor at the University of Namur, Belgium, for the Clinical Project Management and Introduction to PRO courses.
Head of hematology-hemostasis laboratory of CHU UCL Namur, Yvoir, Belgium. Professor at the Université catholique de Louvain and the Université de Namur. Associate editor of Thrombosis Journal. Member of the Groupe d’Intérêt en Hémostase Périopératoire (GIHP). Founder member and coordinator of the Namur Thrombosis and Hemostasis Center (NTHC). Main topics of research: direct oral anticoagulants, heparin-induced thrombocytopenia, extracellular vesicles.
She obtained her degree in Veterinary medicine at the University of Liege in 1999. In 2008 she received the title of PhD in biological sciences at the University of Louvain la Neuve. Her research focuses on cryopreservation of in vitro bovine embryos. In 2009, with Prof Carlos Graux, she developed a biobank structure in CHU UCL Namur- Godinne site. The main objective of this structure is to promote clinical and scientific research, especially translational research. She assumes the coordinator function of the biobank.
Last modified: September 10, 2019